Clinical Trial Update: TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion [Phase 2, Phase 3]

View source ↗

Summary

The TOP-Study evaluated ex vivo tacrolimus perfusion to treat ischemia-reperfusion injury in marginal liver grafts (Phase 2/3). The trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Liver Disease
• Ischemia-reperfusion Injury

Drugs mentioned

• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Terminal Liver Disease, Ischemia Reperfusion Injury | Phase 2, Phase 3 | Status: TERMINATED